Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

PJ Online | News: Topics for NICE appraisal should be in line with NHS priorities

Home > PJ (current issue) > News / Daily News | Search

Return to PJ Online Home Page

The Pharmaceutical Journal
Vol 268 No 7204 p895-899
29 June 2002

This article
Reprint
Photocopy


News summary

Related websites
National Institute for Clinical Excellence (www.nice.org.uk)


Topics for NICE appraisal should be in line with NHS priorities

Topics selected for review by the National Institute for Clinical Excellence should be in line with national service frameworks and there should be a move away from focusing on individual products, the Association of the British Pharmaceutical Industry believes.

The ABPI's suggestion is just one of a number of ideas that it has put to the Department of Health, as part of a consultation exercise on how the appraisal process and selection of topics should be reformed (PJ, 9 March, p315).

In NICE's own response to the DoH consultation it welcomed moves to make the process of selecting topics more open and transparent, and agreed that the selection of topics should more closely follow priorities for the National Health Service.

The institute also said that anyone with an interest in the workings of NICE should be able to recommend topics for selection, and has urged the DoH to consider a further consultation on the selection of topics for clinical guidelines.

NICE has also backed DoH proposals to refer new technologies at an earlier stage, and has suggested that drugs entering phase III trials should be brought to the attention of the technology appraisals group.

However, the ABPI remains concerned by the proposals to appraise new pharmaceuticals at such an early stage. It said that in some cases NICE was appraising medicines too early, using either an immature or inadequate evidence base from which it was difficult to draw conclusions.

Back to Top

Home | Journals | News | Notice-board | Search | Jobs  Classifieds | Site Map | Contact us

©The Pharmaceutical Journal

Citation: The Pharmaceutical Journal URI: 20007154

Rate this article 

Click to rate

  • 1 star out of 5
  • 2 stars out of 5
  • 3 stars out of 5
  • 4 stars out of 5
  • 5 stars out of 5

0 out of 5 stars

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Foundation in Pharmacy Practice

    Foundation in Pharmacy Practice

    A practical and succinct overview of the principal pharmacy practice topics, for new pharmacy students.

    £33.00Buy now
  • Pharmacy in Public Health

    Pharmacy in Public Health

    Pharmacy in Public Health focuses on the important topics in public health relevant to all pharmacists.

    £33.00Buy now
  • Pharmacy Registration Assessment Questions 2

    Pharmacy Registration Assessment Questions 2

    Pharmacy Registration Assessment Questions 2 features more than 400 entirely new, closed book and calculation questions. It can be used in conjunction with the previous volume or on its own. All questions are in line with current GPhC guidance, enabling you to prepare for the pharmaceutical pre-registration exam with confidence.

    £35.00Buy now

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Rate
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.